Ser5
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.7.9
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser5  -  ID3 (human)

Site Information
___MkALsPVRGCyE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 451011

In vivo Characterization
Methods used to characterize site in vivo:
[32P] bio-synthetic labeling ( 16 ) , immunoprecipitation ( 3 ) , mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , mass spectrometry (in vitro) ( 3 ) , mutation of modification site ( 16 )
Disease tissue studied:
breast cancer ( 5 ) , HER2 positive breast cancer ( 1 ) , luminal A breast cancer ( 1 ) , luminal B breast cancer ( 1 ) , breast cancer, surrounding tissue ( 1 ) , breast cancer, triple negative ( 1 ) , lung cancer ( 5 ) , non-small cell lung cancer ( 5 )
Relevant cell line - cell type - tissue:
B lymphocyte-spleen ( 16 ) , breast ( 1 ) , BT-20 (breast cell) ( 5 ) , BT-549 (breast cell) ( 5 ) , Calu 6 (pulmonary) ( 5 ) , EC (endothelial) ( 3 ) , H2009 (pulmonary) ( 5 ) , H2077 (pulmonary) ( 5 ) , H2887 (pulmonary) ( 5 ) , H322M (pulmonary) ( 5 ) , HCC1359 (pulmonary) ( 5 ) , HCC1937 (breast cell) ( 5 ) , HCC2279 (pulmonary) ( 5 ) , HCC4006 (pulmonary) ( 5 ) , HeLa (cervical) ( 2 , 8 ) , HOP62 (pulmonary) ( 5 ) , Jurkat (T lymphocyte) ( 4 , 6 , 7 , 9 , 10 , 11 , 12 , 13 , 14 , 15 ) , MCF-7 (breast cell) ( 5 ) , MDA-MB-231 (breast cell) ( 5 ) , MDA-MB-468 (breast cell) ( 5 ) , NCI-H1395 (pulmonary) ( 5 ) , NCI-H1568 (pulmonary) ( 5 ) , NCI-H157 (pulmonary) ( 5 ) , NCI-H1648 (pulmonary) ( 5 ) , NCI-H1666 (pulmonary) ( 5 ) , NCI-H2030 (pulmonary) ( 5 ) , NCI-H2172 (pulmonary) ( 5 ) , NCI-H322 (pulmonary) ( 5 ) , NCI-H520 (squamous) ( 5 ) , NCI-H647 (pulmonary) ( 5 ) , PC9 (pulmonary) ( 5 )

Upstream Regulation
Putative in vivo kinases:
CDK2 (human) ( 16 ) , Pyk2 (human) ( 3 )
Kinases, in vitro:
CDK2 (human) ( 16 ) , Pyk2 (human) ( 3 )

Downstream Regulation
Effects of modification on ID3:
protein stabilization ( 3 )
Effects of modification on biological processes:
cell cycle regulation ( 16 ) , transcription, altered ( 16 )

References 

1

Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62
27251275   Curated Info

2

Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94
25159151   Curated Info

3

Das JK, Felty Q (2014) PCB153-Induced Overexpression of ID3 Contributes to the Development of Microvascular Lesions. PLoS One 9, e104159
25090023   Curated Info

4

Mertins P, et al. (2013) Integrated proteomic analysis of post-translational modifications by serial enrichment. Nat Methods 10, 634-7
23749302   Curated Info

5

Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68
22617229   Curated Info

6

Zhou J (2011) CST Curation Set: 12495; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

7

Zhou J (2011) CST Curation Set: 12496; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

8

Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5
21712546   Curated Info

9

Possemato A (2010) CST Curation Set: 9698; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

10

Possemato A (2010) CST Curation Set: 9700; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

11

Possemato A (2010) CST Curation Set: 9569; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

12

Possemato A (2010) CST Curation Set: 9568; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

13

Possemato A (2010) CST Curation Set: 9563; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

14

Possemato A (2010) CST Curation Set: 9566; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

15

Possemato A (2010) CST Curation Set: 9567; Year: 2010; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

16

Deed RW, et al. (1997) Regulation of Id3 cell cycle function by Cdk-2-dependent phosphorylation. Mol Cell Biol 17, 6815-21
9372912   Curated Info

Developed with grants from  NIH Logo and literature mining with Linguamatics  I2E Logo Creative Commons License PhosphoSite, created by Cell Signaling Technology is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 3.0 Unported License.

©2003-2024 Cell Signaling Technology, Inc.